TNXP up 11.76%

 TNXP up today

11share

0.6073 AVG

0.37 market 

(39.07% down) 

avg volume 24.6M 

today 4.58M

market cap 7.49M 

(1) Tonix initiates Phase II trial for emergency cocaine intoxication treatment ( August 20 prices up to 0.85$  107M volume) 

Tonix Pharmaceuticals has initiated a Phase II clinical trial for TNX-1300, a treatment for acute cocaine intoxication. This trial is a single-blind, placebo-controlled, proof-of-concept study being conducted in emergency departments across six academic medical centers in the U.S. The study aims to enroll 60 patients and will compare the safety and efficacy of TNX-1300 to a placebo12.

Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, immunology, and infectious diseases. 

The company has received a consensus rating of “Buy” from analysts1. 

They have several promising candidates in their pipeline, including treatments for fibromyalgia and cocaine intoxication23.

However, like many biopharmaceutical companies, Tonix faces challenges such as regulatory hurdles and the need for successful clinical trials. Their stock has experienced significant volatility, which is common in this sector1.

Overall, Tonix Pharmaceuticals shows potential, but it’s important to consider the inherent risks in investing in clinical-stage biotech companies.

If you have any specific questions or need more details, feel free to ask!